Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures
Abstract The incidence of iodinated contrast media (ICM)-related adverse drug reactions (ADRs) varies significantly by procedure type. Compared other procedure types, cerebrovascular interventional procedures substantially increase the incidence of contrast-induced encephalopathy (0.38-2.90%). The a...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-12048-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849237797647417344 |
|---|---|
| author | Ai-bin. Guo Zhi-qi. Yang Bin. Zhao Yuan-ming. Li Ya-xuan. Wei Shao-ju. Shao Guo-zhen. Zhang Hui-sheng. Chen Rong. Yin |
| author_facet | Ai-bin. Guo Zhi-qi. Yang Bin. Zhao Yuan-ming. Li Ya-xuan. Wei Shao-ju. Shao Guo-zhen. Zhang Hui-sheng. Chen Rong. Yin |
| author_sort | Ai-bin. Guo |
| collection | DOAJ |
| description | Abstract The incidence of iodinated contrast media (ICM)-related adverse drug reactions (ADRs) varies significantly by procedure type. Compared other procedure types, cerebrovascular interventional procedures substantially increase the incidence of contrast-induced encephalopathy (0.38-2.90%). The associations of ioversol (nonionic low-osmolal ICM) with central nervous system (CNS) ADRs and iodixanol (nonionic ios-osmolal ICM) with cutaneous ADR manifestations have been establishe. This study aimed to compare the incidence of CNS ADRs and evaluate the occurrence, extent, and risk factors for ADRs associated with ioversol and iodixanol use during cerebrovascular interventional procedures. We conducted a prospective study involving 1,015 participants with suspected cerebrovascular diseases from July 2019 to July 2022. Participants underwent cerebrovascular interventional procedures with either iodixanol or ioversol administration. Data on ioversol and iodixanol-related CNS ADRs, data on other ADRs, and participants’ baseline information were collected. Out of 848 participants (average age, 61.5 ± 12.6 years; 205 females) who received ICM, 16.7% (142 of 848) experienced CNS ADRs. Compared with iodixanol, ioversol was associated with a greater rate of CNS ADRs (12.6% vs. 21.1%, P = 0.001, RR = 1.666). Iodixanol was associated with higher rates of numbness and blurred vision (29.1% vs. 14.9%, P = 0.042), whereas ioversol was associated with higher incidences of headache and overall ADRs during the procedures (20.0% vs. 46.0%, P = 0.002). Logistic regression analysis revealed that a history of allergic diseases was a risk factor for iodixanol-related ADRs (odds ratio [OR], 2.5; 95% confidence interval [CI]: 1.2–4.9; P = 0.010). Severe cerebral vascular stenosis (OR, 2.8; 95% CI: 1.8–4.4; P < 0.001), female sex (OR, 0.5; 95% CI: 0.3–0.8; P = 0.005) and relatively young age (OR, 0.97; 95% CI: 0.95–0.99; P = 0.004) were risk factors for ioversol-related ADRs. Iodixanol appears to have a lower likelihood of causing ICM-related CNS ADRs than does ioversol during cerebrovascular interventional procedures. |
| format | Article |
| id | doaj-art-bec2889d6f5f46b58e15aa9f77577486 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-bec2889d6f5f46b58e15aa9f775774862025-08-20T04:01:51ZengNature PortfolioScientific Reports2045-23222025-07-0115111010.1038/s41598-025-12048-wComparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional proceduresAi-bin. Guo0Zhi-qi. Yang1Bin. Zhao2Yuan-ming. Li3Ya-xuan. Wei4Shao-ju. Shao5Guo-zhen. Zhang6Hui-sheng. Chen7Rong. Yin8Department of Neurology, Gansu Provincial Central HospitalDepartment of Neurology, Gansu Provincial Central HospitalDepartment of Neurology, Gansu Provincial Central HospitalDepartment of Neurology, Gansu Provincial Central HospitalDepartment of Neurology, Gansu Provincial Central HospitalDepartment of Neurology, the 940th Hospital of Joint Logistics Support force of Chinese People’s Liberation ArmyDepartment of Neurology, the 940th Hospital of Joint Logistics Support force of Chinese People’s Liberation ArmyDepartment of Neurology, General Hospital of Northern Theater CommandDepartment of Neurology, Gansu Provincial Central HospitalAbstract The incidence of iodinated contrast media (ICM)-related adverse drug reactions (ADRs) varies significantly by procedure type. Compared other procedure types, cerebrovascular interventional procedures substantially increase the incidence of contrast-induced encephalopathy (0.38-2.90%). The associations of ioversol (nonionic low-osmolal ICM) with central nervous system (CNS) ADRs and iodixanol (nonionic ios-osmolal ICM) with cutaneous ADR manifestations have been establishe. This study aimed to compare the incidence of CNS ADRs and evaluate the occurrence, extent, and risk factors for ADRs associated with ioversol and iodixanol use during cerebrovascular interventional procedures. We conducted a prospective study involving 1,015 participants with suspected cerebrovascular diseases from July 2019 to July 2022. Participants underwent cerebrovascular interventional procedures with either iodixanol or ioversol administration. Data on ioversol and iodixanol-related CNS ADRs, data on other ADRs, and participants’ baseline information were collected. Out of 848 participants (average age, 61.5 ± 12.6 years; 205 females) who received ICM, 16.7% (142 of 848) experienced CNS ADRs. Compared with iodixanol, ioversol was associated with a greater rate of CNS ADRs (12.6% vs. 21.1%, P = 0.001, RR = 1.666). Iodixanol was associated with higher rates of numbness and blurred vision (29.1% vs. 14.9%, P = 0.042), whereas ioversol was associated with higher incidences of headache and overall ADRs during the procedures (20.0% vs. 46.0%, P = 0.002). Logistic regression analysis revealed that a history of allergic diseases was a risk factor for iodixanol-related ADRs (odds ratio [OR], 2.5; 95% confidence interval [CI]: 1.2–4.9; P = 0.010). Severe cerebral vascular stenosis (OR, 2.8; 95% CI: 1.8–4.4; P < 0.001), female sex (OR, 0.5; 95% CI: 0.3–0.8; P = 0.005) and relatively young age (OR, 0.97; 95% CI: 0.95–0.99; P = 0.004) were risk factors for ioversol-related ADRs. Iodixanol appears to have a lower likelihood of causing ICM-related CNS ADRs than does ioversol during cerebrovascular interventional procedures.https://doi.org/10.1038/s41598-025-12048-wIodinated contrast mediaDrug-related adverse reactionsCentral nervous system adverse drug reactionsCerebrovascular interventional procedures |
| spellingShingle | Ai-bin. Guo Zhi-qi. Yang Bin. Zhao Yuan-ming. Li Ya-xuan. Wei Shao-ju. Shao Guo-zhen. Zhang Hui-sheng. Chen Rong. Yin Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures Scientific Reports Iodinated contrast media Drug-related adverse reactions Central nervous system adverse drug reactions Cerebrovascular interventional procedures |
| title | Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures |
| title_full | Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures |
| title_fullStr | Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures |
| title_full_unstemmed | Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures |
| title_short | Comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures |
| title_sort | comparison of ioversol and iodixanol related adverse drug reactions in cerebrovascular interventional procedures |
| topic | Iodinated contrast media Drug-related adverse reactions Central nervous system adverse drug reactions Cerebrovascular interventional procedures |
| url | https://doi.org/10.1038/s41598-025-12048-w |
| work_keys_str_mv | AT aibinguo comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT zhiqiyang comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT binzhao comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT yuanmingli comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT yaxuanwei comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT shaojushao comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT guozhenzhang comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT huishengchen comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures AT rongyin comparisonofioversolandiodixanolrelatedadversedrugreactionsincerebrovascularinterventionalprocedures |